# Defensive rotation: Dow hits record highs while tech bleeds — accumulate Eli Lilly

_AI-generated trading idea · LONG · LLY_

> Canonical page: https://commonquant.ai/research/for-you/defensive-rotation-dow-hits-record-highs-while-tech-bleeds-a--59f44d44-548b-416f-8408-62dbc19a040d

The old-school Dow Jones hit a record high thanks to defensive stocks like Eli Lilly, while tech stocks took a hit. With the economy slowing down and unemployment ticking up, investors are moving their money into healthcare companies whose sales are protected by government Medicare coverage.

## Idea

While the tech-heavy Nasdaq is falling due to chip struggles, the Dow Jones hit a record high, signaling a classic rotation into defensive sectors. Eli Lilly just hit new highs thanks to huge results and Medicare inclusion for its GLP-1 drugs, insulating its revenue from economic downturns. With only 57,000 jobs added in June and unemployment rising to 4.2%, the economy is clearly cooling off. Buying dominant healthcare names like Eli Lilly protects a portfolio during an economic slowdown while the government-backed Medicare inclusion guarantees steady sales.

## Advanced Analysis

### Verdict: Eli Lilly's fundamentals deserve respect, but the entry hasn't earned a trade yet

The defensive-rotation case has real substance: FY2025 revenue was $65.2B, up 44.7% year over year, net income reached $20.6B at a 31.7% margin, and the dividend has grown roughly 15.3% annually to a trailing $6.69 per share — elite economics for a supposed defensive name. But the strongest point against is that the compiled rules produced zero entries across 60, 24, and 12-month windows on 1,232 real daily bars, and the parameter-sensitivity evaluation ran out of time, so no robust parameter setup was established; the strategy also expresses a technical reversal on QQQ rather than the healthcare-rotation thesis itself. The latest quarter cuts both ways — gross margin rose 3.8 points to 85.8%, but net margin fell 6.5 points to 30.9% and ROE slipped from 23.7% to 20.9%. Meanwhile, the ownership filing covering the period ended June 30, 2026 (a lagged view, not current) shows insiders as net open-market sellers by roughly $2.9M, the opposite of conviction buying. Nothing is live to buy: LLY last closed at $1,129.76, $62.55 below the $1,192.31 20-day average that is the only unmet entry condition, while RSI (14) at 31.9 already clears the at-or-below-40 gate and first support sits at $1,110.57. A confirmed close above the 20-day average with the other conditions intact — or a stabilized margin line in the late-October Q3 report — would flip this from watch-list to actionable; thesis support and fundamentals trend score moderately well, but trade readiness and trigger proximity stay low until the threshold confirms.

#### Conviction score breakdown

Composite score computed by the server from the applicable evidence-tier dimensions.

| Measure | Value |
| --- | ---: |
| Thesis support | 70/100 |
| Trade readiness | 25/100 |
| Risk quality | 55/100 |
| Trigger proximity | 30/100 |
| Fundamentals trend | 60/100 |
| Score | 48/100 |
| Composite Score | 48/100 |
| Evidence Tier | rules\_not\_triggered |

#### Decision scenarios

Bull, base, and bear cases synthesized from the cited evidence tier. Likelihoods are rounded evidence-weighted judgments, not statistically calibrated forecasts.

| Measure | Value |
| --- | ---: |
| Evidence Tier | rules\_not\_triggered |

### Trade now: LLY entry is one condition away — here's the exact level

Nothing to buy yet — this is a watch-list setup, and the plan is to let the entry come to you. LLY last closed at $1,129.76, sitting between first support at $1,110.57 and first resistance at $1,134.31. Three of the four entry conditions are already live: the 20-day channel condition is met, RSI (14) is at 31.9 versus the at-or-below-40 threshold (cleared by 8.1 points), and the down-close-versus-open condition resolves on the daily bar itself. The one blocker is structural: price needs to be above the 20-day average, currently $1,192.31 — that's $62.55 above the last close. So waiting means exactly this: LLY either recovers above roughly $1,192 while momentum stays below 40 and tags but holds first support, or there is no entry.

On fills, the mechanics are fixed. The stop is a 2.4% loss on the position; the profit target is 4.8%, and a close at or above first resistance also exits long. That gives an effective reward-to-risk of about 2-to-1 on any triggered entry, with position risk capped at roughly 2.4% of account under the fixed-risk sizing rule and a 25% maximum position. A close back above first support ($1,110.57) after crossing below it is a secondary stop exit.

Context on why the entry is worth waiting for: the idea argues that defensive rotation — Dow record highs on the back of healthcare names like Eli Lilly while the Nasdaq bleeds — protects capital in a cooling economy, with Medicare inclusion for GLP-1 drugs cited as the revenue backstop. The latest quarter supports the margin story (gross margin rose to 85.8%, up 3.8 points quarter over quarter) but also shows net margin compressing to 30.9% from 37.4%, a 6.5-point drop. That mix argues against chasing: let the price condition, not the headline narrative, decide the entry. Insiders were net open-market sellers by about $2.9M in the most recent ownership filing covering the period ended June 30, 2026, which reinforces the case for waiting for a technically defined level rather than buying conviction outright.

#### LLY price and trigger map

Uses the idea timeframe and keeps price levels on the price axis.

| Measure | Value |
| --- | ---: |
| Ticker | LLY |
| Timeframe | 1d |

### The bull case still has support

The idea's defensive-rotation thesis has real fundamental support. Eli Lilly's full-year 2025 revenue was $65.2B, up 44.7% year over year, with a gross margin of 83.0% and net income of $20.6B — a 31.7% net margin. The momentum continued into 2026: Q2 revenue reached $22.97B (up from $19.80B in Q1) and quarterly…

#### LLY Return on equity

Return on equity trend from CommonQuant fundamentals/XBRL data; +124.6% from first to latest point.

| Measure | Value |
| --- | ---: |
| 2008-12-31 | \-0.3075084969648396% |
| 2009-06-30 | \0.13533878504672897% |
| 2009-09-30 | \0.3446138313982837% |
| 2009-09-30 | \0.09508329126703684% |
| 2009-12-31 | \0.45445287812457347% |
| 2009-12-31 | \0.09610196004325322% |
| 2010-03-31 | \0.1192949924968697% |
| 2010-06-30 | \0.13178900471896282% |
| 2010-09-30 | \0.10502599653379548% |
| 2010-12-31 | \0.4081624437412945% |
| 2011-03-31 | \0.07577758321252745% |
| Latest Value | \0.07577758321252745% |
| Change Pct | \124.642435562095% |
| Ticker | LLY |
| Timeframe | reported periods |

#### LLY sector percentile check

Ranks LLY against 972 companies in its sector using CommonQuant fundamentals.

| Measure | Value |
| --- | ---: |
| Return on equity | \90.94650205761316th percentile |
| Gross margin | \79.8932384341637th percentile |
| Revenue growth (YoY) | 75th percentile |
| Ticker | LLY |
| Sector | Health Care |
| Peer Count | 972 |

### Scores

- **Conviction score breakdown:** 48
- **Thesis support:** 70
- **Trade readiness:** 25
- **Risk quality:** 55
- **Trigger proximity:** 30
- **Fundamentals trend:** 60

### Watch items

- **LLY — LLY daily close vs SMA (20)**
- **LLY — RSI (14)**
- **LLY — First support level**
- **LLY — Insider net open-market value (next ownership filing after 2026-06-30)**
- **LLY — Net margin, Q3 (period ending 2026-09-30)**

## Key details

- Symbols: LLY
- Timeframes: D1
- Tags: \#stocks, \#defensive, \#healthcare

## Community

- Upvotes: 112
- Views: 2,668
- Copies: 0
- Cosigns: 0

## News sources

- [U.S. economy added 57,000 jobs in June, less than expected; unemployment rate at 4.2%](https://www.cnbc.com/2026/07/02/jobs-report-june-2026-.html) — CNBC
- [Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results](https://finance.yahoo.com/healthcare/articles/eli-lilly-hits-highs-glp-142311427.html) — Yahoo Finance
- [Dow rises more than 400 points to record, Nasdaq falls again as chipmakers struggle: Live updates](https://www.cnbc.com/2026/07/01/stock-market-today-live-updates.html) — CNBC

## Discussion (4)

**@chosen\_bull22** · 1 upvotes

For LLY, I would watch whether the 1d move can hold after 2026-07-03.

## Related

- [LLY trade ideas](https://commonquant.ai/markets/lly)
- [Latest market news](https://commonquant.ai/news)

## About CommonQuant Research

Ideas and Advanced Analysis are generated with fresh, LLM-selected news headlines and grounded in SEC XBRL fundamentals and peer percentiles. Strategies built from these ideas are automatically backtested (over a timeframe-dependent historical window with walk-forward tuning) and stress-tested before they can go live, then monitored against the news hourly while they run.